Form 4: ADAR1 Capital Divests Keros Therapeutics Stake

ADAR1 Capital Management and related entities reported the planned sale of over 5.3 million shares of Keros Therapeutics common stock for approximately $95.6 million.

Summary

• ADAR1 Capital Management, LLC, along with ADAR1 Partners, LP, ADAR1 SPV I, LP, Spearhead Insurance Solutions IDF, LLC, and Daniel Schneeberger, reported the disposition of Keros Therapeutics, Inc. common stock.
• The transaction, scheduled for October 15, 2025, involves the sale of a total of 5,389,264 shares of common stock.
• The shares were sold at a price of $17.75 per share, totaling approximately $95,659,082.
• The disposition includes 4,391,237 shares from ADAR1 Partners, LP, 254,669 shares from ADAR1 SPV I, LP, and 743,358 shares from Spearhead Insurance Solutions IDF, LLC.
• Following these transactions, the reporting persons will beneficially own 0 shares of Keros Therapeutics common stock.
• The transaction was made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan for the purchase or sale of equity securities.

Sentiment

Score: 3

Explanation: The complete divestment of a significant stake by a 10% owner and related entities, including a director, is a strong negative signal. While pre-planned, the action itself suggests a lack of continued conviction or a strategic exit, which is typically viewed unfavorably by investors.

Negatives

• A significant 10% owner and related entities are completely divesting their entire reported common stock holdings in Keros Therapeutics.
• The planned sale by a major institutional investor and director could signal a lack of long-term conviction or a strategic exit, potentially impacting investor sentiment negatively.

Future Outlook

NA

Management Comments

• Daniel Schneeberger, Manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, signed the filing on behalf of the reporting persons, indicating his involvement in the entities overseeing the transaction.

Industry Context

This Form 4 filing reports a specific insider transaction and does not provide broader industry context or trends. It reflects a decision by a significant investor regarding their stake in Keros Therapeutics.

Related Party Transactions

• The disposition of shares involves ADAR1 Capital Management, LLC, ADAR1 Partners, LP, ADAR1 SPV I, LP, Spearhead Insurance Solutions IDF, LLC, and Daniel Schneeberger, all of whom are related reporting persons with beneficial ownership ties.

Stakeholder Impact

• Shareholders may react negatively to the news of a major 10% owner and director completely divesting their stake, potentially leading to downward pressure on the stock price.
• The transaction could influence market perception of Keros Therapeutics' future prospects among institutional investors.

Key Dates

Recommendation

The complete divestment of over 5.3 million shares by a 10% owner and related entities, including a director, represents a significant lack of confidence or a strategic exit from the investment. This large-scale insider selling, even if pre-planned, typically signals potential headwinds or a belief that the stock is fully valued, prompting a 'sell' recommendation for investors to reconsider their positions.

Keywords

Keros Therapeutics, KROS, ADAR1 Capital Management, Insider Trading, Form 4, Stock Sale, Beneficial Ownership, 10b5-1 Plan